Close
CDMO Safety Testing 2026
Novotech

Elsevier introduces authoritative scientific Datasets to fuel innovation and business-critical decisions in life sciences, chemicals and other research-intensive industries

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

MGS Advances Healthcare Product Development with Hybrid Tooling

MGS, a healthcare-focused contract development and manufacturing organization, has...

Aptar Advances Pharmaceutical Packaging as N-Sorb Technology Gains Patent Approval

Aptar Active Material Science, a division of AptarGroup, Inc.,...

MHRA Launches AI Sandbox to Accelerate Drug Development

The Medicines and Healthcare products Regulatory Agency (MHRA) has...
- Advertisement -

Elsevier, a global leader in scientific information and data analytics, has announced a new offering of enriched and authoritative scientific Datasets to power data applications that solve R&D challenges. Elsevierโ€™s Datasets enable researchers, data scientists and practice leaders to answer R&D questions with greater speed and precision across many industries, including life sciences, energy, chemicals and materials, and technology. Use cases span a variety of data science and analytical projects including identifying disease targets using natural language processing, predicting molecule efficacy and toxicity using neural networks, predictive modeling, Key Opinion Leader (KOL) analysis and more.

โ€œR&D-intensive businesses are excited by the possibilities of generative AI, predictive modeling and other areas at the vanguard of data science,โ€ commented Gino Ussi, President of Corporate Markets, Elsevier. โ€œHowever, to deliver high-quality analytics and well-trained AI models, data scientists must still devote much of their time to sourcing quality data. This is laborious due to the volume and range of research literature and comes with risk if the data is not from a trusted, validated source. Elsevierโ€™s Datasets address this challenge, drawing on our expertise in curating peer-reviewed science for more than 140 years and partnering with the research community.โ€

Pharma, chemicals, energy, applied materials and technology companies can extract scientific insights by integrating data from Elsevier into private, secure computational ecosystems, including custom applications and third-party tools. Application-ready Datasets for chemistry, biology and 22 other disciplines come from a variety of sources, including:

  • 19 million full-text articles from peer-reviewed journals
  • 17 million author profiles
  • 1.8 billion cited references
  • 333 million chemical substances and reactions
  • 86 million bioactivities and biomedical records
    35 million chemical patents

Elsevierโ€™s Datasets accelerate discovery and innovation in multiple domains. Leaders in pharmaceuticals, chemicals, technology and other industries are licensing Elsevier data for a variety of use cases. For example, in drug discovery, Datasets are used for target selection and discovery, confirming or identifying lead candidates, and in performing protein-ligand binding QSAR modeling. Pharmaceutical companies can also benefit from applying Datasets to pharmacovigilance, clinical trial design and to inform market access strategy. In materials science and materials informatics, Datasets support selecting the right material for a given application or product design based on property prediction and analysis of relevant datasets. Spanning all disciplines, Datasets enable KOL identification and rising star selection; predictive modeling (e.g., material property predictions or drug-drug interactions); training sets; knowledge graph creation; enterprise, federated and/or semantic search; business intelligence dashboards; and algorithm and neural network training.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

MGS Advances Healthcare Product Development with Hybrid Tooling

MGS, a healthcare-focused contract development and manufacturing organization, has...

Aptar Advances Pharmaceutical Packaging as N-Sorb Technology Gains Patent Approval

Aptar Active Material Science, a division of AptarGroup, Inc.,...

MHRA Launches AI Sandbox to Accelerate Drug Development

The Medicines and Healthcare products Regulatory Agency (MHRA) has...

CPHI Americas Relocates to Miami to Strengthen Global Industry Connectivity

Informa Markets has announced that CPHI Americas will relocate...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป